Author Login

Correspondence to Author: Brieuc Sauetois, Andreia Loehr, Simon P. Watfkins, Hélène Schedroeder and Wassieam Abida  

Mansoura University,Egypt.

Introduction:  In patients with metastatic castration-resistant prostate cancer (mCRPC) linked to BRCA alterations, PARP inhibitors like rucaparib have been thoroughly studied. The clinical efficacy of these drugs has also been assessed in patients with mCRPC linked to changes in other nonBRCA DNA damage repair (DDR) genes, such as RAD51B. Depending on the particular DDR gene that has been changed, there is probably a varying sensitivity to PARP inhibition; however, because these gene modifications are not common, there is little research in this area. Here, we report a mCRPC patient with a truncating rearrangement of RAD51B who responded to treatment with the PARP inhibitor rucaparib in the TRITON2 trial in terms of both radiography and PSA.We used next-generation sequencing (NGS) of tissue and plasma to examine the patients’ response characteristics, circulating tumor DNA (ctDNA) fraction, and tumor genomes over an extended period of time. The ctDNA proportion decreases during response and is correlated with both radiographic and PSA response. No possible genetic mechanism of acquired drug.

Keywords:prostate cancer; PARP inhibitors; RAD51B.

Citation:

Brieuc Sauetois. A Case Study Of A Patient With Metastatic CastrationResistant Prostate Cancer With A Rad51b Alteration And Their Clinical Reaction To Rucaparib. Journal Of Cancer And Tumor Research 2025.